Investment Recommendations - North Exchange has clear medium to long-term allocation value, suggesting a dual strategy of offense and defense[2] - Key sectors to focus on include commercial aerospace, electric new energy, automotive, electronics, and engineering machinery[2] Fund Performance and Holdings - As of Q4 2025, 11 themed open-end funds held a total of 44 North Exchange A-shares, with 9 new stocks added to the portfolio[3] - Approximately 40% of the heavy-weighted stocks maintained the same number of fund coverage, indicating strong asset appeal and stickiness[3] - The total market value of the top ten heavy-weighted stocks decreased by 40% quarter-on-quarter to 1.505 billion yuan[3] Market Trends and Valuation - In Q4 2025, 25% of the heavy-weighted stocks were newly added, reflecting an accelerated adjustment pace compared to Q3 2025[3] - 57% of the heavy-weighted stocks had a market capitalization below 5 billion yuan, showing a preference for small to mid-cap stocks[3] - Valuation dispersion is significant, with P/E ratios ranging from -4244x to 304x among the heavy-weighted stocks[3] Risk Factors - Potential risks include macroeconomic fluctuations, liquidity issues, and corporate earnings falling short of expectations[2]

Core Insights - The Beijing Stock Exchange (BSE) has achieved significant growth over its four years, focusing on serving innovative small and medium-sized enterprises [1][2] - The launch of the Huaxia BSE Innovation Small and Medium Enterprises Selected Two-Year Open-End Mixed Fund provides investors with a channel to benefit from the BSE's growth [1][4] Group 1: BSE Growth and Market Performance - The BSE has seen a steady increase in the number of listed companies, with average daily trading volume rising from 1 billion to between 20 billion and 30 billion [1] - The average profit of newly listed companies has been increasing year-on-year, indicating a positive trend in company performance [1] - The investor structure has diversified, with public funds and quantitative funds entering the market [1] Group 2: Fund Performance and Strategy - The Huaxia BSE Selected Two-Year Open-End Fund, established on November 23, 2021, has achieved a scale of 1.004 billion as of September 30, 2025, with a one-year net value growth rate of 152.80% and a three-year growth rate of 266.42% [2][3] - The fund's performance is attributed to its focus on high-quality, high-growth, and low-valuation stocks, particularly in sectors like medical beauty, automotive parts, high-end equipment, and new materials [3] - The fund will have a total scale limit of 1.5 billion during its open period to maintain stability and manage liquidity effectively [4] Group 3: Future Outlook - The BSE's growth potential is expected to be bolstered by policy support, improved market ecology, and the concentration of quality enterprises [4] - The fund aims to leverage its research advantages to select innovative and high-potential growth targets, allowing investors to share in the long-term growth dividends of innovative small and medium enterprises [4]

Investment Rating - The report maintains an "Outperform" rating for the North Exchange market [5] Core Views - The North Exchange is experiencing a rebound in the North 50 index, with a total of 280 listed companies and a total market capitalization of 920.978 billion yuan, reflecting a month-on-month increase of 6.0% [13][18] - The North 50 index's price-to-earnings ratio (PE-TTM) is 49.53 times, placing it at the 95.25 percentile level over the past two years, while the price-to-book ratio (PB-MRQ) is 10.27 times, at the 97.52 percentile level [24][27] - The North Exchange's trading activity has decreased, with a monthly trading volume of 15.458 billion shares and a trading amount of 365.334 billion yuan, representing a month-on-month decline of 40.6% and 40.7% respectively [18][19] Market Overview - In October 2025, the North Exchange saw a decrease in trading activity, with the average daily trading amount dropping by 23.2% [19] - The North 50 index and the North Specialized New Index rose by 3.54% and 2.28% respectively, while the Shanghai and Shenzhen 300 index remained unchanged [32][36] Industry Performance - The report indicates that all industries on the North Exchange experienced gains, except for the non-ferrous metals sector, with significant increases in transportation, construction materials, home appliances, pharmaceutical biology, and machinery equipment [36] - The communication sector has the highest median PE ratio at 123 times, followed by light industry manufacturing at 94 times and non-ferrous metals at 88 times [24][27] New Listings and Market Dynamics - Three new companies were listed this month: Aomeisen, Changjiang Energy Technology, and Taikai Ying, bringing the total number of listed companies to 280 [13][36] - The report highlights the ongoing efforts to enhance market functionality and vitality, including the introduction of new financial products and the promotion of mergers and acquisitions [4][32]

Group 1: Securities Firms' Financing Progress - Multiple listed securities firms are advancing refinancing efforts, indicating a pressing need for capital replenishment in the industry [1] - Tianfeng Securities has completed a private placement of 1.476 billion shares, increasing its registered capital from 8.666 billion yuan to 10.142 billion yuan [1] - Other firms like Guotai Junan, Haitong Securities, and Guolian Minsheng have also raised significant funds through private placements, totaling 10 billion yuan, 4 billion yuan, and 2 billion yuan respectively [1] Group 2: Fund Purchase Restrictions - High-performing funds are collectively imposing purchase limits, with notable fund manager Ge Lan's fund suspending large subscriptions to stabilize operations [2] - Over 30 actively managed equity funds have announced purchase restrictions since July, reflecting a cautious approach to the market's high valuation [2] - This trend may lead to a shift in capital flow within the pharmaceutical sector, as fund managers seek to cool down the market after a strong rebound in innovative drug stocks [2] Group 3: Performance of Equity Funds - The equity market has seen structural opportunities, with 99% of equity funds reporting positive returns over the past year, averaging a return of 34.06% [3] - Notably, several funds focused on the Beijing Stock Exchange have achieved exceptional returns, with some funds doubling their net value [3] - This performance indicates a robust market sentiment towards innovative small and medium enterprises, potentially attracting more capital into the equity market [3] Group 4: Leadership Changes in East Wu Securities - Xue Zhen, the president of East Wu Securities, has been appointed as the chairman of East Wu Fund, reflecting the strategic importance of fund operations within the securities firm [4][5] - This leadership change is expected to enhance business synergy between East Wu Securities and East Wu Fund, optimizing the governance structure [5] - The integration of resources may improve the comprehensive financial service capabilities of East Wu Securities, aligning with the trend of convergence between securities asset management and public funds [5]

Core Viewpoint - The article highlights the performance of equity funds in the A-share market, noting that many funds have reached historical highs in net value as of July 2025, driven by a strong upward trend in major stock indices [4][5]. Group 1: Performance of Equity Funds - As of the end of July 2025, 1,985 equity funds (established for over a year) reached historical highs in net value [4]. - The Shanghai Composite Index rose by 3.74%, the Shenzhen Component Index by 5.20%, and the ChiNext Index by 8.14% in July 2025 [4]. - Among the top-performing funds from January to July 2025, 834 funds were analyzed, with 74% meeting the criteria for the top 20 performers [5]. Group 2: Top Performing Funds - The top three funds for the period of January to July 2025 are: 1. Zhongyin Hong Kong Stock Connect Medical Mixed Fund A (Code: 020397) with a return of 113.51% [5][10]. 2. Yongying Medical Innovation Selected Mixed Fund A (Code: 015915) with a return of 113.30% [5]. 3. Guangfa Growth Leading One-Year Holding Mixed Fund A (Code: 016243) with a return of 97.33% [5]. - The Zhongyin fund had a scale of approximately 139 million yuan as of the second quarter of 2025 and has achieved a cumulative return of 88.72% since its inception [10][11]. Group 3: Recent Year Performance - In the past year, all top 20 funds have achieved over 100% returns, with six being North Exchange theme funds and five being medical theme funds [12]. - The top three funds for the past year are: 1. CITIC Construction North Exchange Selected Two-Year Open Mixed Fund A (Code: 016303) with a return of 202.70% [12][17]. 2. Huitianfu North Exchange Innovation Selected Two-Year Open Mixed Fund A (Code: 014279) with a return of 152.49% [12]. 3. Wanjia North Exchange Wise Selection Two-Year Open Mixed Fund A (Code: 014277) with a return of 139.98% [12]. Group 4: Three-Year Performance - The top three funds over the past three years are: 1. Huitianfu North Exchange Innovation Selected Two-Year Open Mixed Fund A (Code: 014279) with a return of 135.25% [19][24]. 2. Jia Shi Mutual Fund Selected Stock A (Code: 006603) with a return of 120.26% [19]. 3. Wanjia North Exchange Wise Selection Two-Year Open Mixed Fund A (Code: 014277) with a return of 108.56% [19]. Group 5: Five-Year Performance - The top three funds over the past five years are: 1. Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund (Code: 004685) with a return of 262.69% [26][31]. 2. Dongwu New Trend Value Line Mixed Fund (Code: 001322) with a return of 183.15% [26]. 3. Dongwu Mobile Internet Mixed A (Code: 001323) with a return of 178.89% [26].

Group 1 - The core viewpoint of the news is that public funds focusing on the North Exchange and innovative pharmaceuticals have shown remarkable performance in the first half of 2025, with specific funds achieving significant returns [1][2]. - The top three performing public funds as of June 30, 2025, are: 1. CITIC Construction Investment North Exchange Selected Two-Year Open Fund with a return of 82.45% 2. Great Wall Pharmaceutical Industry Selected Fund with a return of 75.18% 3. Huaxia North Exchange Innovative Small and Medium Enterprises Selected Fund with a return of 72.16% [1]. - Over the past three, five, and ten years, the top-performing funds have been: 1. Huaxia North Exchange Innovative Small and Medium Enterprises Selected Fund with a return of 175.64% 2. Jinyuan Shun'an Yuanqi Fund with a return of 297.96% 3. Huashang New Trend Preferred Fund with a return of 361.6% [1]. Group 2 - The North Exchange theme funds have performed exceptionally well, with two of the top three funds being North Exchange theme funds. CITIC Construction Investment North Exchange Selected Fund ranks first [2]. - The top holdings of CITIC Construction Investment North Exchange Selected Fund include companies listed on the North Exchange, indicating a strong focus on this market [2]. - The fund manager of CITIC Construction Investment has expressed optimism about the long-term investment potential of North Exchange companies, while also emphasizing the need to manage external uncertainties [2][3]. Group 3 - Funds focused on innovative pharmaceuticals, particularly in the innovative drug sector, have also shown strong performance, with six out of the top ten funds investing heavily in this area [4]. - The Great Wall Pharmaceutical Industry Selected Fund, managed by Liang Furui, has become the runner-up in performance, with significant holdings in companies that have seen their stock prices double this year [4]. - The fund manager believes that the innovative drug sector is at a pivotal moment, with improvements in overseas research collaborations and financial reports expected to drive future growth [4].

Core Insights - The A-share market in the first half of 2025 exhibited a distinct structural trend, with mixed funds' performance reflecting this trend prominently [1] - The top-performing mixed funds were dominated by themes related to the Beijing Stock Exchange and the pharmaceutical sector [1] Fund Performance Summary - The top ten mixed funds in terms of returns showed significant gains, with the leading fund, CITIC Construction Investment Beijing Stock Exchange Selected Two-Year Open A, achieving a return of 82.45% [2] - Other notable funds included Great Wall Pharmaceutical Industry Selected A with a return of 75.18% and Huaxia Beijing Stock Exchange Innovative Small and Medium Enterprises Selected Two-Year Open with a return of 72.16% [2] - The average return of the six pharmaceutical-themed funds in the top ten was 66.78%, indicating strong performance in this sector [3] Fund Declines Summary - The fund with the largest loss was Galaxy Junrong I, which saw a decline of 37.89%, while the Qianhai Open Source Artificial Intelligence Theme Fund and Pioneer Ju You A followed with declines of 20.57% and 18.42%, respectively [3] - Several funds managed by Caitong Fund, including Caitong Value Momentum A, experienced significant declines, with the largest drop being 16.05% [4] Market Outlook - The market is expected to show a fluctuating upward trend in the second half of 2025, driven by policy support and verification of economic conditions [6] - A-share valuations are currently at a medium historical level, suggesting a relatively high investment cost-performance ratio compared to mature overseas markets [6] - The importance of understanding industry cycles and policy directions is emphasized for capturing investment opportunities amidst market differentiation [6]

Core Insights - The public fund market showed significant profitability in the first half of 2025, with 87% of funds achieving positive returns, highlighting a strong market recovery [1][9][10] - The top-performing funds were dominated by innovative drug and North Exchange theme funds, indicating a trend towards specialized investment strategies [2][3][4][5] Fund Performance - The best-performing fund was Huatai-PineBridge Hong Kong Advantage Selection A, with a net value growth of 86.48%, followed closely by CITIC Securities North Exchange Selection with 82.45% and Great Wall Pharmaceutical Industry Selection A with 75.18% [3][4] - Seven out of the top ten funds were heavily invested in innovative drugs, while two were focused on North Exchange themes, showcasing the effectiveness of concentrated investment strategies [4][5] Market Trends - The first half of 2025 saw a notable performance from sectors such as innovative drugs, North Exchange, humanoid robots, and new consumption, with these themes alternating in prominence [2][3][10] - Analysts predict that the positive trends for innovative drugs and North Exchange themes are likely to continue into the second half of the year, supported by structural opportunities in these sectors [7][8] Overall Market Dynamics - A total of 12,571 funds were analyzed, with 10,949 achieving positive returns, reflecting a broad-based recovery in the public fund market [9] - The market exhibited a "barbell" characteristic, with both high-growth technology stocks and low-valuation, high-dividend stocks performing well, particularly in the banking sector [10] Sector Performance - Certain sectors, such as real estate and food and beverage, underperformed, leading to lower returns for funds heavily invested in these areas [11] - The bond market transitioned from a bull market to a more volatile environment, resulting in weaker performance for fixed-income funds [11]

Core Viewpoint - The performance of the fund industry in the first half of 2025 has been strong, with significant returns driven by sectors such as pharmaceuticals and the North Exchange, despite challenges from tariff policies [2][4][7]. Fund Performance - The average return of all market fund products was 4.28%, with the best-performing fund achieving over 85% return and the worst losing more than 20%, resulting in a performance spread of over 106% [2]. - Notable funds include: - Huatai-PineBridge Hong Kong Advantage Selection A: 85.64% - CITIC Construction North Exchange Selection Two-Year Open A: 82.45% - Great Wall Pharmaceutical Industry Selection A: 75.18% - Huaxia North Exchange Innovative SMEs Selection Two-Year Open: 72.16% - Bank of China Hong Kong Stock Connect Pharmaceutical A: 70.08% [6][16]. Sector Highlights - The pharmaceutical sector has shown remarkable performance, with the core driver being the explosive growth of the Hong Kong innovative pharmaceutical sector [4][7]. - The North Exchange theme funds have also performed well, benefiting from ongoing reforms and the growth of specialized and innovative enterprises [7][19]. Fund Manager Insights - Fund managers have noted that the pharmaceutical industry is expected to continue demonstrating resilience and technological attributes over the next 2-3 years, with supportive policies for innovative drugs likely to improve conditions across various sectors [7][14]. - The performance of passive funds is increasingly challenging that of actively managed funds, with notable examples being: - Huaan Pharmaceutical Biotechnology A: 66.44% - Huatai-PineBridge National Index Hong Kong Stock Connect Innovative Drug ETF: 58.77% [3][11]. Market Outlook - The market is expected to shift from a risk-averse mindset to one focused on opportunities, with a broader range of sectors showing potential for growth, including technology and cyclical industries [18][19]. - Analysts predict a "dumbbell" structure for market opportunities in the second half of the year, highlighting both high-growth technology stocks and stable dividend-paying blue-chip stocks [19].

Group 1 - The Beijing Stock Exchange (BSE) has shown strong performance this year, with related thematic funds seeing net value increases of over 30%, and some exceeding 70% [1] - As of June 12, the BSE 50 Index has risen by 37.25% this year, outperforming major indices such as the Shanghai Composite Index and Shenzhen Component Index [1] - Nearly 40 BSE-themed funds have an average net value increase of approximately 33.53% this year, with specific funds like CITIC Construction Investment and Huaxia showing net value increases of over 70% [1] Group 2 - 24 BSE funds have recorded net value increases exceeding 30% this year, including funds from Invesco Great Wall and GF Securities [2] - Since their inception, several funds have achieved net value increases of over 100%, with some exceeding 120% [2] - Analysts indicate that the BSE is gradually attracting more active incremental capital, with a need for increased institutional investor participation compared to the Sci-Tech Innovation Board and ChiNext [2]